CoChat

Rescue of a Dystrophin-like Protein by Exon Skipping In Vivo Restores GABAA-receptor Clustering in the Hippocampus of the mdx Mouse

Vaillend, Cyrille, Perronnet, Caroline, Ros, Carine, Gruszczynski, Carole, Goyenvalle, Aurélie, Laroche, Serge, Danos, Olivier, Garcia, Luis, Peltekian, Elise · 2010 · Molecular Therapy
Cited by 59

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2010.134

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Hinton, 2000, Poor verbal working memory across intellectual level in boys with Duchenne dystrophy, Neurology, 54, 2127, 10.1212/WNL.54.11.2127 · DOI · Paper page
  2. Desguerre, 2009, Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up, PLoS ONE, 4, e4347, 10.1371/journal.pone.0004347 · DOI · Paper page
  3. Anderson, 2002, Brain function in Duchenne muscular dystrophy, Brain, 125, 4, 10.1093/brain/awf012 · DOI · Paper page
  4. Perronnet, 2010, Dystrophins, utrophins and associated scaffolding complexes: Role in mammalian brain and implications for therapeutic strategies, J Biomed Biotech
  5. Miranda, 2009, Reorganization of inhibitory synapses and increased PSD length of perforated excitatory synapses in hippocampal area CA1 of dystrophin-deficient mdx mice, Cereb Cortex, 19, 876, 10.1093/cercor/bhn135 · DOI · Paper page
  6. Knuesel, 1999, Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice), Eur J Neurosci, 11, 4457, 10.1046/j.1460-9568.1999.00887.x · DOI · Paper page
  7. Grady, 2006, Cerebellar synaptic defects and abnormal motor behavior in mice lacking α- and β-dystrobrevin, J Neurosci, 26, 2841, 10.1523/JNEUROSCI.4823-05.2006 · DOI
  8. Sekiguchi, 2009, A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice, Brain, 132, 124, 10.1093/brain/awn253 · DOI · Paper page
  9. Fritschy, 2003, Pre- and post-synaptic mechanisms regulating the clustering of type A γ-aminobutyric acid receptors (GABAA receptors), Biochem Soc Trans, 31, 889, 10.1042/bst0310889 · DOI
  10. Craig, 2007, Neurexin-neuroligin signaling in synapse development, Curr Opin Neurobiol, 17, 43, 10.1016/j.conb.2007.01.011 · DOI · Paper page
  11. Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol, 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
  12. Daoud, 2009, Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression, Hum Mol Genet, 18, 3779, 10.1093/hmg/ddp320 · DOI
  13. Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum Mutat, 30, 293, 10.1002/humu.20918 · DOI · Paper page
  14. Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 · DOI · Paper page
  15. Wang, 2003, Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain, Gene Ther, 10, 1528, 10.1038/sj.gt.3302011 · DOI
  16. Aartsma-Rus, 2003, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum Mol Genet, 12, 907, 10.1093/hmg/ddg100 · DOI · Paper page
  17. Santiago, 2005, Afferent connections of the amygdalopiriform transition area in the rat, J Comp Neurol, 489, 349, 10.1002/cne.20637 · DOI
  18. Lidov, 1993, The distribution of dystrophin in the murine central nervous system: an immunocytochemical study, Neuroscience, 54, 167, 10.1016/0306-4522(93)90392-S · DOI · Paper page
  19. Knuesel, 2001, Alterations in dystrophin and utrophin expression parallel the reorganization of GABAergic synapses in a mouse model of temporal lobe epilepsy, Eur J Neurosci, 13, 1113, 10.1046/j.0953-816x.2001.01476.x · DOI · Paper page
  20. Danos, 2008, AAV vectors for RNA-based modulation of gene expression, Gene Ther, 15, 864, 10.1038/gt.2008.69 · DOI
  21. Desmaris, 2004, Prevention of neuropathology in the mouse model of Hurler syndrome, Ann Neurol, 56, 68, 10.1002/ana.20150 · DOI · Paper page
  22. Brünig, 2002, GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin, J Neurosci, 22, 4805, 10.1523/JNEUROSCI.22-12-04805.2002 · DOI · Paper page
  23. Lévi, 2002, Dystroglycan is selectively associated with inhibitory GABAergic synapses but is dispensable for their differentiation, J Neurosci, 22, 4274, 10.1523/JNEUROSCI.22-11-04274.2002 · DOI · Paper page
  24. Sassoè-Pognetto, 2000, Colocalization of multiple GABA(A) receptor subtypes with gephyrin at postsynaptic sites, J Comp Neurol, 420, 481, 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5 · DOI · Paper page
  25. Bolte, 2006, A guided tour into subcellular colocalization analysis in light microscopy, J Microsc, 224, 213, 10.1111/j.1365-2818.2006.01706.x · DOI · Paper page

Cited by

See all 59

Metadata

Authors
Vaillend, C., Perronnet, C., Ros, C., Gruszczynski, C., Goyenvalle, A., Laroche, S., Danos, O., Garcia, L., & Peltekian, E.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2010-09
Volume
18
Issue
9
Pages
1683-1688
ISSN
1525-0016
Cited by
59
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.